Extensive pregnancy-related off-treatment time in women with
familial hypercholesterolaemia

J 2026

Extensive pregnancy-related off-treatment time in women with familial hypercholesterolaemia

KLEVMOEN, Marianne; van Lennep Jeanine ROETERS; Martin Proven BOGSRUD; Elisabeth Kleivhaug VESTERBEKKMO; Eva Kristine Ringdal PEDERSEN et al.

Základní údaje

Originální název

Extensive pregnancy-related off-treatment time in women with familial hypercholesterolaemia

Autoři

Vydání

Atherosclerosis, Clare, ELSEVIER SCI IRELAND LTD, 2026, 0021-9150

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.700 v roce 2024

Označené pro přenos do RIV

Ano

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Familial hypercholesterolaemia; Pregnancy; Breastfeeding; Pregnancy-related off-treatment time

Štítky

14110114, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 1. 4. 2026 13:52, Mgr. Tereza Miškechová

Anotace

V originále

Background and aims: Women with familial hypercholesterolaemia (FH) lose substantial treatment time during their reproductive years as most lipid-lowering therapies are contraindicated from the preconception through the end of breastfeeding. We examined the duration of real-life pregnancy-related off-treatment time in 27 women with FH in Norway. Methods: Women with FH in Norway who had completed the ongoing FH-FEMINA study (ClinicalTrials.gov ID NCT05367310) were included. Women were followed from 36th week of gestation and until one year after delivery or until end of breastfeeding. Information on use of medication before, during and after the current and previous pregnancies was collected. Pregnancy-related off-treatment time was calculated from discontinuation of lipid-lowering therapy when planning pregnancy, throughout pregnancy, and after delivery. Results: The total duration of pregnancy-related off-treatment time after all childbirths (median 1, range 1-3) per woman was a median of 2.9 years (25th-75th percentile; 1.6-4.0), ranging from 0.8 to 12 years. The pregnancy itself accounted for median of 42.1% of the pregnancy-related off-treatment time, whereas the time before and after pregnancy accounted for a median of 57.9% (range 11.4% to 91.2%). When including untreated years in childhood and/or prior to diagnosis, the lifelong off-treatment time represented a median of 66.3% (range 41.9 to 100%) of lifetime without treatment. Conclusion: Early diagnosis and initiation of treatment is essential in girls with FH to compensate for pregnancy-related off-treatment time later in life. To minimize these pregnancy-related off-treatment periods, healthcare professionals should support women with FH to resume lipid-lowering therapy immediately after breastfeeding and between pregnancies. In addition, more knowledge on the potential effects of statin use during pregnancy and breastfeeding on maternal and offspring health is urgently needed.

Citovat

KLEVMOEN, Marianne; van Lennep Jeanine ROETERS; Martin Proven BOGSRUD; Elisabeth Kleivhaug VESTERBEKKMO; Eva Kristine Ringdal PEDERSEN; Anders HOVLAND; Janneke W C M MULDER; Hilde Kristin BREKKE; Per Ole IVERSEN; Martina VACLOVA; Michal VRABLIK; Tomáš FREIBERGER; Kjetil RETTERSTOL a Kirsten B HOLVEN. Extensive pregnancy-related off-treatment time in women with familial hypercholesterolaemia. Atherosclerosis. Clare: ELSEVIER SCI IRELAND LTD, 2026, roč. 415, April 2026, s. 1-5. ISSN 0021-9150. Dostupné z: https://doi.org/10.1016/j.atherosclerosis.2026.120668.

@article{2564282,
   author = {Klevmoen, Marianne and Roeters, van Lennep Jeanine and Bogsrud, Martin Proven and Vesterbekkmo, Elisabeth Kleivhaug and Pedersen, Eva Kristine Ringdal and Hovland, Anders and Mulder, Janneke W C M and Brekke, Hilde Kristin and Iversen, Per Ole and Vaclova, Martina and Vrablik, Michal and Freiberger, Tomáš and Retterstol, Kjetil and Holven, Kirsten B},
   article_location = {Clare},
   article_number = {April 2026},
   doi = {https://doi.org/10.1016/j.atherosclerosis.2026.120668},
   keywords = {Familial hypercholesterolaemia; Pregnancy; Breastfeeding; Pregnancy-related off-treatment time},
   language = {eng},
   issn = {0021-9150},
   journal = {Atherosclerosis},
   title = {Extensive pregnancy-related off-treatment time in women with familial hypercholesterolaemia},
   url = {https://www.sciencedirect.com/science/article/pii/S0021915026000341?pes=vor&utm_source=clarivate&getft_integrator=clarivate},
   volume = {415},
   year = {2026}
}

TY  - JOUR
ID  - 2564282
AU  - Klevmoen, Marianne - Roeters, van Lennep Jeanine - Bogsrud, Martin Proven - Vesterbekkmo, Elisabeth Kleivhaug - Pedersen, Eva Kristine Ringdal - Hovland, Anders - Mulder, Janneke W C M - Brekke, Hilde Kristin - Iversen, Per Ole - Vaclova, Martina - Vrablik, Michal - Freiberger, Tomáš - Retterstol, Kjetil - Holven, Kirsten B
PY  - 2026
TI  - Extensive pregnancy-related off-treatment time in women with familial hypercholesterolaemia
JF  - Atherosclerosis
VL  - 415
IS  - April 2026
SP  - 1-5
EP  - 1-5
PB  - ELSEVIER SCI IRELAND LTD
SN  - 00219150
KW  - Familial hypercholesterolaemia
KW  - Pregnancy
KW  - Breastfeeding
KW  - Pregnancy-related off-treatment time
UR  - https://www.sciencedirect.com/science/article/pii/S0021915026000341?pes=vor&utm_source=clarivate&getft_integrator=clarivate
N2  - Background and aims: Women with familial hypercholesterolaemia (FH) lose substantial treatment time during their reproductive years as most lipid-lowering therapies are contraindicated from the preconception through the end of breastfeeding. We examined the duration of real-life pregnancy-related off-treatment time in 27 women with FH in Norway. Methods: Women with FH in Norway who had completed the ongoing FH-FEMINA study (ClinicalTrials.gov ID NCT05367310) were included. Women were followed from 36th week of gestation and until one year after delivery or until end of breastfeeding. Information on use of medication before, during and after the current and previous pregnancies was collected. Pregnancy-related off-treatment time was calculated from discontinuation of lipid-lowering therapy when planning pregnancy, throughout pregnancy, and after delivery. Results: The total duration of pregnancy-related off-treatment time after all childbirths (median 1, range 1-3) per woman was a median of 2.9 years (25th-75th percentile; 1.6-4.0), ranging from 0.8 to 12 years. The pregnancy itself accounted for median of 42.1% of the pregnancy-related off-treatment time, whereas the time before and after pregnancy accounted for a median of 57.9% (range 11.4% to 91.2%). When including untreated years in childhood and/or prior to diagnosis, the lifelong off-treatment time represented a median of 66.3% (range 41.9 to 100%) of lifetime without treatment. Conclusion: Early diagnosis and initiation of treatment is essential in girls with FH to compensate for pregnancy-related off-treatment time later in life. To minimize these pregnancy-related off-treatment periods, healthcare professionals should support women with FH to resume lipid-lowering therapy immediately after breastfeeding and between pregnancies. In addition, more knowledge on the potential effects of statin use during pregnancy and breastfeeding on maternal and offspring health is urgently needed.
ER  -

KLEVMOEN, Marianne; van Lennep Jeanine ROETERS; Martin Proven BOGSRUD; Elisabeth Kleivhaug VESTERBEKKMO; Eva Kristine Ringdal PEDERSEN; Anders HOVLAND; Janneke W C M MULDER; Hilde Kristin BREKKE; Per Ole IVERSEN; Martina VACLOVA; Michal VRABLIK; Tomáš FREIBERGER; Kjetil RETTERSTOL a Kirsten B HOLVEN. Extensive pregnancy-related off-treatment time in women with familial hypercholesterolaemia. \textit{Atherosclerosis}. Clare: ELSEVIER SCI IRELAND LTD, 2026, roč.~415, April 2026, s.~1-5. ISSN~0021-9150. Dostupné z: https://doi.org/10.1016/j.atherosclerosis.2026.120668.

Přehled o publikaci